The gut-thyroid axis in autoimmune thyroid diseases: from intestinal immune tolerance breakdown to thyroid homing

Autoimmune thyroid diseases (AITD), mainly Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), are among the most common organ-specific autoimmune disorders. Genetic susceptibility and environmental factors, including iodine intake, cannot fully explain AITD pathogenesis. The gut-thyroid axis has emerged as a key regulatory network. This axis is bidirectional, with thyroid dysfunction also influencing gut microecology. In AITD, gut microbiota dysbiosis is commonly characterized by a decrease in short-chain fatty acid (SCFA)-producing beneficial bacteria and an increase in lipopolysaccharide (LPS)-producing bacteria, which may lead to reduced SCFAs and elevated LPS. This “metabolic duality” may drive intestinal barrier damage, systemic low-grade inflammation, and imbalance of regulatory T (Treg) cells and T helper 17 (Th17)/T helper 1 (Th1) cells. This review proposes a putative three-stage conceptual model: intestinal sensitization, circulatory amplification and homing reprogramming, and thyroid homing and local injury. Gut-derived CCR6 + and CXCR3 + pathogenic T cells are proposed to migrate to the thyroid via chemokine axes (e.g., CCL20-CCR6 and CXCL10-CXCR3) and integrin pathways (e.g., α4β1-VCAM-1). In the thyroid, HT is characterized predominantly by Th1-type responses, whereas GD involves a prominent Th17 component; however, both diseases involve multiple T-cell subsets, B cells, autoantibodies, and complex local immune microenvironments. In GD, thyrotropin receptor (TSHR) autoantibodies play a central pathogenic role. The thyroid may actively participate in immune injury and may serve as a local autoantibody production site. Therapeutic strategies targeting the gut microecology, including probiotics, fecal microbiota transplantation, and SCFA supplementation, show promise as adjunctive treatments. However, prospective longitudinal studies and direct histological evidence of gut-derived T cell homing are needed. This review provides an integrated, hypothesis-generating framework for understanding AITD pathogenesis and highlights novel intervention targets.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.2003968
Primary Topic
Thyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The gut-thyroid axis in autoimmune thyroid diseases: from intestinal immune tolerance breakdown to thyroid homing

Jiaqi Guan, Wenyong Liao, Shaohong Chen, Zhennan Zhou
4 links
Frontiers in Immunology
Thyroid Disorders and Treatments
article

The gut-thyroid axis in autoimmune thyroid diseases: from intestinal immune tolerance breakdown to thyroid homing

Jiaqi Guan, Wenyong Liao, Shaohong Chen, Zhennan Zhou
article en

Abstract

Autoimmune thyroid diseases (AITD), mainly Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), are among the most common organ-specific autoimmune disorders. Genetic susceptibility and environmental factors, including iodine intake, cannot fully explain AITD pathogenesis. The gut-thyroid axis has emerged as a key regulatory network. This axis is bidirectional, with thyroid dysfunction also influencing gut microecology. In AITD, gut microbiota dysbiosis is commonly characterized by a decrease in short-chain fatty acid (SCFA)-producing beneficial bacteria and an increase in lipopolysaccharide (LPS)-producing bacteria, which may lead to reduced SCFAs and elevated LPS. This “metabolic duality” may drive intestinal barrier damage, systemic low-grade inflammation, and imbalance of regulatory T (Treg) cells and T helper 17 (Th17)/T helper 1 (Th1) cells. This review proposes a putative three-stage conceptual model: intestinal sensitization, circulatory amplification and homing reprogramming, and thyroid homing and local injury. Gut-derived CCR6 + and CXCR3 + pathogenic T cells are proposed to migrate to the thyroid via chemokine axes (e.g., CCL20-CCR6 and CXCL10-CXCR3) and integrin pathways (e.g., α4β1-VCAM-1). In the thyroid, HT is characterized predominantly by Th1-type responses, whereas GD involves a prominent Th17 component; however, both diseases involve multiple T-cell subsets, B cells, autoantibodies, and complex local immune microenvironments. In GD, thyrotropin receptor (TSHR) autoantibodies play a central pathogenic role. The thyroid may actively participate in immune injury and may serve as a local autoantibody production site. Therapeutic strategies targeting the gut microecology, including probiotics, fecal microbiota transplantation, and SCFA supplementation, show promise as adjunctive treatments. However, prospective longitudinal studies and direct histological evidence of gut-derived T cell homing are needed. This review provides an integrated, hypothesis-generating framework for understanding AITD pathogenesis and highlights novel intervention targets.

Frontiers in ImmunologyVol. 17
Zhejiang Chinese Medical University (CN), Beijing University of Chinese Medicine (CN)
Good health and well-being
Thyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon